-
公开(公告)号:US20220213092A1
公开(公告)日:2022-07-07
申请号:US17552396
申请日:2021-12-16
Applicant: AbbVie Inc.
Inventor: David A. DeGoey , Felix DeAnda, Jr. , Amanda W. Dombrowski , Igor Dubovyk , Stephen N. Greszler , Dimitri Khrakovsky , Chih-Hung Lee , James N. Newton , Elizabeth L. Noey , Akinori Okano , Kevin B. Sippy , Andrew J. Souers , Longcheng Wang , Noel S. Wilson , Jeffery A. Zablocki
IPC: C07D471/04 , C07D519/00 , C07D487/04
Abstract: The present invention provides for compounds of formula (I) wherein A, R1, R2, R4, W, m, and n have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL and/or SLL.
-
公开(公告)号:US12172992B2
公开(公告)日:2024-12-24
申请号:US18187489
申请日:2023-03-21
Applicant: AbbVie Inc.
Inventor: Zhiguo Bian , Jason P. Burke , Zhaozhong J. Jia , Xingyu Jiang , Matthew H. Katcher , Venkat Reddy Mali , Violeta L. Marin , Elizabeth L. Noey , Alexey A. Rivkin , Kevin R. Woller , Ashley M. Adams , Shahab Mortezaei , Joshua N. Payette
IPC: C07D413/14 , A61P35/02
Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4A, R4b, and R5, are as defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL.
-
公开(公告)号:US20240158368A1
公开(公告)日:2024-05-16
申请号:US18379351
申请日:2023-10-12
Applicant: AbbVie Inc.
Inventor: David A. Degoey , Michael R. Schrimpf , David J. Hardee , Jacob Ludwig , Eric R. Miller , Timothy R. Hodges , Alberto Munoz , Sarah J. Perlmutter , Huan-Qiu X. Li , Alvin Jang , Elizabeth L. Noey , Gregory A. Gfesser , Edgars Jecs , Robert G. Schmidt , Justin D. Dietrich , Xenia B. Searle , Boguslaw P. Nocek , Andrew Bogdan
IPC: C07D401/12 , A61P31/14
CPC classification number: C07D401/12 , A61P31/14
Abstract: Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.
-
公开(公告)号:US20240109877A1
公开(公告)日:2024-04-04
申请号:US18187489
申请日:2023-03-21
Applicant: AbbVie Inc.
Inventor: Zhiguo Bian , Jason P. Burke , Zhaozhong J. Jia , Xingyu Jiang , Matthew H. Katcher , Venkat Reddy Mali , Violeta L. Marin , Elizabeth L. Noey , Akinori Okano , Alexey A. Rivkin , Spencer O. Scholz , Kevin R. Woller , Xianrui Zhao , Ashley M. Adams , Berenger Biannic , Shahab Mortezaei , Joshua N. Payette , Jeffery A. Zablocki
IPC: C07D413/14 , A61P35/02
CPC classification number: C07D413/14 , A61P35/02
Abstract: The present invention provides for compounds of formula (I)
wherein R1, R2, R3, R4A, R4b, and R5, are as defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL.
-
-
-